Cargando…
Bevacizumab increases the risk of anastomosis site leakage in metastatic colorectal cancer
BACKGROUND: Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor and is used in combination with first-line chemotherapy in the treatment of metastatic colorectal cancer. One of the side effects of bevacizumab is gastrointestinal perforation. This study was desig...
Autores principales: | Kim, Seijong, Shin, Jung Kyong, Park, Yoonah, Huh, Jung Wook, Kim, Hee Cheol, Yun, Seong Hyeon, Lee, Woo Yong, Cho, Yong Beom |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639472/ https://www.ncbi.nlm.nih.gov/pubmed/36353568 http://dx.doi.org/10.3389/fonc.2022.1018458 |
Ejemplares similares
-
Correlation between T stage and lymph node metastasis in rectal
cancer treated with preoperative chemoradiotherapy
por: Kim, Seijong, et al.
Publicado: (2022) -
Risk Factors of Anastomotic Leakage and Long-Term Survival After Colorectal Surgery
por: Park, Jong Seob, et al.
Publicado: (2016) -
Can CCRT/RT Achieve Favorable Oncologic Outcome in Rectal Cancer Patients With High Risk Feature After Local Excision?
por: Kim, Seijong, et al.
Publicado: (2022) -
Neoadjuvant chemoradiotherapy determines the prognostic impact of anastomotic leakage in advanced rectal cancer
por: Oh, Bo Young, et al.
Publicado: (2022) -
Elevated Carcinoembryonic Antigen at the Time of Recurrence as a Poor Prognostic Factor in Colorectal Cancer: A Propensity Score Matching Analysis
por: Shin, Jung Kyong, et al.
Publicado: (2022)